358 related articles for article (PubMed ID: 32092462)
1. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Das S; Jiang X; Jiang W; Ting TY; Polli JE
Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
[TBL] [Abstract][Full Text] [Related]
2. Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy.
Das S; Pu X; Jiang X; Jiang W; Tung R; Ting TY; Polli JE
Epilepsy Behav; 2019 Jan; 90():197-203. PubMed ID: 30579779
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy.
Das S; Jiang X; Jiang W; Tung R; Ting TY; Polli JE
Epilepsy Behav; 2022 Mar; 128():108587. PubMed ID: 35151189
[TBL] [Abstract][Full Text] [Related]
5. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
Holtkamp M; Theodore WH
Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
[TBL] [Abstract][Full Text] [Related]
6. Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.
Karalis V; Macheras P; Bialer M
CNS Drugs; 2014 Jan; 28(1):69-77. PubMed ID: 24092569
[TBL] [Abstract][Full Text] [Related]
7. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.
Yamada M; Welty TE
Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417
[TBL] [Abstract][Full Text] [Related]
8. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
9. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Kwan P; Palmini A
Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
[TBL] [Abstract][Full Text] [Related]
10. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
11. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Hartung DM; Middleton L; Svoboda L; McGregor JC
CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
[TBL] [Abstract][Full Text] [Related]
12. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
[TBL] [Abstract][Full Text] [Related]
13. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
14. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy.
Chen B; Choi H; Hirsch LJ; Katz A; Legge A; Buchsbaum R; Detyniecki K
Epilepsy Behav; 2017 Nov; 76():24-31. PubMed ID: 28931473
[TBL] [Abstract][Full Text] [Related]
15. Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy.
Das S; Guo D; Jiang X; Jiang W; Shu Y; Ting TY; Polli JE
Pharm Res; 2020 Feb; 37(3):60. PubMed ID: 32103380
[TBL] [Abstract][Full Text] [Related]
16. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
[TBL] [Abstract][Full Text] [Related]
17. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Makus KG; McCormick J
Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
[TBL] [Abstract][Full Text] [Related]
18. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
[TBL] [Abstract][Full Text] [Related]
19. The use of generic medication in epilepsy: a review of potential issues and challenges.
Van Paesschen W; Hauman H; Lagae L
Eur J Paediatr Neurol; 2009 Mar; 13(2):87-92. PubMed ID: 18790656
[TBL] [Abstract][Full Text] [Related]
20. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Contin M; Alberghini L; Candela C; Benini G; Riva R
Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
